| Literature DB >> 33411263 |
Nicola Lamberti1, Sofia Straudi2, Roberto Manfredini3, Alfredo De Giorgi4, Vincenzo Gasbarro5, Paolo Zamboni6, Fabio Manfredini1,2.
Abstract
We studied the outcomes of peripheral artery disease (PAD) patients enrolled in a structured in-home walking program right before the lockdown due to the SARS-CoV-2 epidemic emergency, to determine whether this intervention ensured the maintenance of mobility even in the case of movement restrictions.We selectively studied 83 patients (age 72 ± 11, males n = 65) enrolled in the program within 9-month before the lockdown. The usual intervention was based on two daily 8-min sessions of slow intermittent in-home walking prescribed in circa-monthly hospital visits. During the lockdown, the program was updated by phone. Six-minute (6MWD) and pain-free walking distance (PFWD) were measured pre- and post-lockdown as well as body weight (BW), blood pressure (BP), and ankle-brachial index (ABI). Sixty-six patients were measured 117 ± 23 days after their previous visit. A safe, pain-free execution of the prescribed sessions was reported (median distance: 74 km). Overall, the 6MWD was stable, while PFWD improved (p < 0.001). The improvement was not related to age/gender, comorbidities, type of home but to the time of enrollment before lockdown. The new-entry subjects (≤ 3 months; n = 35) obtained significant improvements post-lockdown for 6MWD and PFWD, while those previously enrolled (> 3 months; n = 31) were stable. Decreased BW with stable BP and ABI values were also recorded, with better outcomes for new-entry subjects. In PAD patients, a structured walking program performed inside home and purposely guided by phone was adhered to by patients and favored mobility and risk factor control during the COVID-19 pandemic, regardless of walking ability, type of home and external conditions.Entities:
Keywords: Cardiovascular diseases; Exercise; Mobility; Peripheral artery disease; Rehabilitation; Risk factors
Mesh:
Year: 2021 PMID: 33411263 PMCID: PMC7788170 DOI: 10.1007/s11739-020-02598-4
Source DB: PubMed Journal: Intern Emerg Med ISSN: 1828-0447 Impact factor: 3.397
The telephone questionnaire and the answers provided by the patients
| Yes (%) | No (%) | |
|---|---|---|
| Did you exercise regularly at least once a day? | 59 (90) | 7 (10) |
| Did you execute more exercise sessions respect to the prescribed ones? | 21 (32) | 45 (68) |
| Did one of your cohabitant exercise with you? | 9 (14) | 57 (86) |
| Did you feel that your claudication is worsened? | 5 (8) | 61 (92) |
| Did you gain weight? | 11 (17) | 55 (83) |
| Did your blood glucose increase?† | 6 (24) | 19 (76) |
| Do you live in the city? | 28 (42) | 38 (58) |
| Does your house/building have a garden? | 60 (91) | 6 (9) |
| Do you have a dog? | 21 (32) | 45 (68) |
| How big is your house? (m2) | 86 ± 21 | |
†Collected only in the sample of diabetes patients
Fig. 1Study flow diagram of participants enrolled in the period June 2019–March 2020
Baseline characteristics of the two subgroups of patients
| Rookies | Veterans | ||
|---|---|---|---|
| Age (years) | 73 ± 6 | 70 ± 14 | 0.20 |
| Weight (kg) | 87 ± 15 | 85 ± 18 | 0.66 |
| BMI (kgm−2) | 30 ± 4 | 29 ± 5 | 0.44 |
| Education, | |||
| Elementary school | 16 (46) | 10 (32) | 0.18 |
| Inferior middle school | 15 (43) | 9 (29) | 0.21 |
| Superior middle school | 3 (9) | 10 (32) | 0.07 |
| Degree | 1 (3) | 2 (7) | 0.41 |
| Risk factors, | |||
| Smoking | 31 (89) | 29 (94) | 0.49 |
| Hypertension | 33 (94) | 28 (91) | 0.55 |
| Hyperlipidaemia | 26 (74) | 21 (68) | 0.56 |
| Diabetes | 14 (40) | 11 (36) | 0.71 |
| Chronic kidney disease | 6 (17) | 7 (23) | 0.58 |
| Family history for CVD | 3 (9) | 6 (19) | 0.09 |
| Comorbidities, | |||
| Coronary heart disease | 16 (45) | 21 (68) | 0.08 |
| Cerebrovascular disease | 7 (20) | 3 (10) | 0.24 |
| Osteoarticular disease | 19 (54) | 19 (61) | 0.58 |
| Rheumatic diseases | 5 (14) | 2 (7) | 0.30 |
| Age-adjusted Charlson Comorbidity Index | 6 ± 2 | 6 ± 2 | 0.88 |
| Pharmacological therapy, | |||
| Antiplatelet | 30 (86) | 27 (87) | 0.91 |
| Anticoagulant | 5 (14) | 4 (13) | 0.82 |
| Peripheral artery disease | |||
| Disease duration (years) | 5 ± 5 | 5 ± 5 | 0.89 |
| Lower limb revascularization | 10 (28) | 8 (26) | 0.80 |
| Leriche-Fontaine stage 2a | 24 (69) | 24 (77) | 0.57 |
| Leriche-Fontaine stage 2b | 9 (31) | 9 (23) | 0.57 |
| ABI more affected limb | 0.64 ± 0.17 | 0.65 ± 0.20 | 0.76 |
| ABI less affected limb | 0.81 ± 0.18 | 0.90 ± 0.26 | 0.16 |
| Pain-free walking distance (m), entry | 174 ± 77 | 136 ± 74 | 0.13 |
| 6-min walking distance (m), entry | 312 ± 53 | 285 ± 91 | 0.32 |
| Pain-free walking distance (m), Pre | 192 ± 84 | 208 ± 103 | 0.46 |
| 6-min walking distance (m), Pre | 319 ± 57 | 318 ± 102 | 0.98 |
BMI body mass index, CVD cardiovascular disease, ABI Ankle-Brachial Index
Within- and between-subgroup differences in rehabilitation outcomes
| Whole population | Rookies | Veterans | |||||
|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | ||
| Weight (kg) | 86 (82–90) | 85 (81–89)* | 87 (82–92) | 86 (81–91)* | 85 (79–91) | 84 (78–91) | 0.64 |
| SBP (mmHg) | 147 (142–151) | 145 (141–149) | 151 (144–158) | 147 (141–153)* | 142 (136–147) | 143 (138–149) | 0.031 |
| DBP (mmHg) | 76 (74–78) | 74 (72–76) | 76 (73–80) | 74 (71–77) | 75 (73–78) | 74 (71–77) | 0.39 |
| ABI worst limb | 0.64 (0.59–0.69) | 0.65 (0.60–0.70) | 0.63 (0.57–0.70) | 0.66 (0.59–0.73) | 0.65 (0.58–0.63) | 0.64 (0.56–0.72) | 0.08 |
| ABI best limb | 0.85 (0.79–0.91) | 0.87 (0.80–0.94) | 0.81 (0.74–0.88) | 0.86 (0.78–0.94)* | 0.90 (0.79–1.00) | 0.89 (0.77–1.01) | 0.07 |
| PFWD (m) | 200 (177–222) | 227 (201–252)* | 192 (163–221) | 230 (199–262)* | 209 (171–246) | 223 (180–265) | 0.023 |
| 6MWD (m) | 318 (298–338) | 323 (302–344) | 319 (299–338) | 332 (311–352)* | 318 (281–355) | 319 (271–366) | 0.007 |
Data are expressed as mean and 95% Confidence Interval
ABI Ankle-Brachial Index, SBP systolic blood pressure, DBP diastolic blood pressure, PFWD pain-free walking distance, 6MWD 6-min walking distance
*Within-group p value < 0.05 obtained with paired-samples t test or Wilcoxon test. Between group comparison in changes analysed with independent samples t test or Mann–Whitney test